These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33606902)

  • 1. Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
    Verma S; Fainberg U; Husain M; Rasmussen S; Rydén L; Ripa MS; Buse JB
    Diabetes Obes Metab; 2021 Jul; 23(7):1677-1680. PubMed ID: 33606902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
    Husain M; Bain SC; Jeppesen OK; Lingvay I; Sørrig R; Treppendahl MB; Vilsbøll T
    Diabetes Obes Metab; 2020 Mar; 22(3):442-451. PubMed ID: 31903692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
    Husain M; Consoli A; De Remigis A; Pettersson Meyer AS; Rasmussen S; Bain S
    Cardiovasc Diabetol; 2022 Apr; 21(1):64. PubMed ID: 35484580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
    Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
    Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.
    Evans LM; Mellbin L; Johansen P; Lawson J; Paine A; Sandberg A
    Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00259. PubMed ID: 34277983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
    Nauck MA; Quast DR
    Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.
    Webb J; Mount J; von Arx LB; Rachman J; Spanopoulos D; Wood R; Tritton T; Massey O; Idris I
    Diabetes Obes Metab; 2022 Feb; 24(2):289-295. PubMed ID: 34668637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
    Bain SC; Mosenzon O; Arechavaleta R; Bogdański P; Comlekci A; Consoli A; Deerochanawong C; Dungan K; Faingold MC; Farkouh ME; Franco DR; Gram J; Guja C; Joshi P; Malek R; Merino-Torres JF; Nauck MA; Pedersen SD; Sheu WH; Silver RJ; Tack CJ; Tandon N; Jeppesen OK; Strange M; Thomsen M; Husain M
    Diabetes Obes Metab; 2019 Mar; 21(3):499-508. PubMed ID: 30284349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
    Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
    Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.
    Westerink J; Matthiessen KS; Nuhoho S; Fainberg U; Lyng Wolden M; Østergaard HB; Visseren F; Sattar N
    Diabetes Care; 2022 May; 45(5):1211-1218. PubMed ID: 35263432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
    Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
    Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
    Riddle MC; Gerstein HC; Xavier D; Cushman WC; Leiter LA; Raubenheimer PJ; Atisso CM; Raha S; Varnado OJ; Konig M; Lakshmanan M; Franek E
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1345-1351. PubMed ID: 33537745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
    Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
    Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
    Rossing P; Bain SC; Bosch-Traberg H; Sokareva E; Heerspink HJL; Rasmussen S; Mellbin LG
    Cardiovasc Diabetol; 2023 Aug; 22(1):220. PubMed ID: 37620807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
    Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB
    Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
    Ferrannini G; Gerstein H; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probstfield J; Riddle MC; Shaw JE; Avezum A; Basile JN; Cushman WC; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pais P; Pīrāgs V; Pogosova N; Raubenheimer PJ; Sheu WH; Rydén L
    Eur Heart J; 2021 Jul; 42(26):2565-2573. PubMed ID: 33197271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
    Strain WD; Frenkel O; James MA; Leiter LA; Rasmussen S; Rothwell PM; Sejersten Ripa M; Truelsen TC; Husain M
    Stroke; 2022 Sep; 53(9):2749-2757. PubMed ID: 35582947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
    Verma S; Al-Omran M; Leiter LA; Mazer CD; Rasmussen S; Saevereid HA; Sejersten Ripa M; Bonaca MP
    Diabetes Obes Metab; 2022 Jul; 24(7):1288-1299. PubMed ID: 35332654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.